Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
Refractory overactive bladder (OAB) after urethrolysis for iatrogenic bladder outlet obstruction (BOO) is a clinical dilemma without established guidelines for management. We sought to evaluate the efficacy of sacral neuromodulation (SNM) in the management of this complex patient population. Retrospective review identified eight patients who underwent SNM secondary to refractory OAB after urethrolysis or sling take-down. SNM was performed with the Interstim device (Medtronic, Minneapolis) using a two-stage implant technique. SNM outcomes were determined subjectively during follow-up. Validated questionnaires were completed to assess symptom bother, patient satisfaction, and quality of life. Statistical analyses were conducted using Stata version 9.0. Six patients had a favorable response to SNM during test stimulation and underwent implantation of the implantable pulse generator (IPG). With follow-up of 15.7 +/- 11.1 months (6-34), all patients significantly improved, with three patients being dry and three patients having one to two urgency incontinence episodes per week. Patient-reported outcomes indicated that patients perceived themselves as very much improved (3) or much improved (3) after SNM, while those failing test stimulation perceived no change. Quality of life and symptom bother were significantly better in SNM responders vs nonresponders. SNM appears to be an effective and viable treatment option in this complex patient population. Further work is needed to determine clinical factors predictive of outcome and durability of response.
Clinical Instructor, Department of Urologic Surgery, Vanderbilt University Medical Center, A-1302 MCN, Nashville, TN 37232-2765, USA. starkman137@comcast.net
Jonathan S
JS
Starkman
John W
JW
Duffy
Christopher E
CE
Wolter
Melissa R
MR
Kaufman
Harriette M
HM
Scarpero
Roger R
RR
Dmochowski
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001521:Behavior Therapy; D003131:Combined Modality Therapy; D004599:Electric Stimulation Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D011788:Quality of Life; D012189:Retrospective Studies; D012447:Sacrum / Q000294:innervation; D053825:Suburethral Slings; D011795:Surveys and Questionnaires; D017211:Treatment Failure; D014521:Urethra / Q000601:surgery*; D001748:Urinary Bladder Neck Obstruction / Q000601:surgery*; D053201:Urinary Bladder, Overactive / Q000628:therapy*; D013520:Urologic Surgical Procedures / Q000009:adverse effects*
D018727:Muscarinic Antagonists